{"schema_version":"secwatch.filing_event.v1","accession":"0001991792-25-000004","form_type":"8-K","ticker":"CGON","cik":"0001991792","company_name":"CG Oncology, Inc.","filed_at":"2025-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.769966+00:00","generated_at":"2026-05-17T08:08:32.959186+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CG Oncology reports 41.8% 24-month CR in Phase 3 BOND-003 for cretostimogene","bullets":["24-month CR rate of 41.8% (46/110) in BCG-unresponsive HR NMIBC; 12 additional CRs since April 2025 AUA.","90% of 12-month responders remained disease-free at 24 months; 96.6% free from progression to muscle-invasive disease.","No Grade 3+ TRAEs or deaths; median TRAE resolution 1 day; 97.3% completed all treatments.","Company plans BLA submission for cretostimogene in HR NMIBC unresponsive to BCG in Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001991792-25-000004","json":"https://secwatch.observer/filing/0001991792-25-000004.json","markdown":"https://secwatch.observer/filing/0001991792-25-000004.md","text":"https://secwatch.observer/filing/0001991792-25-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1991792/000199179225000004/0001991792-25-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1991792/000199179225000004/ck0001991792-20250905.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:08:32.959186+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}